Almirall logo

Almirall(OTC) LBTSF

Market Cap$3.34BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+76%
5 Year+7%
1 Year+70%
1 Month+0%
$15.35
+0.00%
+0.00Today
Almirall last closing stock price
MetricPriceDate
Last closeUSD 15.352026-06-12
Almirall stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 15.352026-02-09
1 month+0%USD 15.352026-02-09
3 month+0%USD 15.352026-02-09
Year to date-0.78%USD 15.472025-12-12
1 year+70.37%USD 9.012025-06-11
3 year+58.57%USD 9.682023-06-09
5 year+6.69%USD 14.392021-05-10
Since inception+75.74%USD 8.732011-08-16

Almirall Financials at a Glance

Market Cap

$3.34BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€1.41B

Net Income (TTM)

€71.72M

EPS (TTM)

$0.32

P/E Ratio

48.03

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Price

$15.35

Volume

5

Open

$15.35

Previous Close

$15.35

Daily Range

$15.35 - $15.35

52-Week Range

$13.36 - $15.47

Estimated Earnings Date

Nov 9, 2026

LBTSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Almirall

Almirall, S.A. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of dermatology-focused pharmaceuticals. The company operates across Europe, the United States, and various international markets, providing treatments for a wide range of skin conditions.

Products and Services
  • Specialized dermatological treatments for conditions like psoriasis and acne
  • Collaborations with partners for innovative therapeutic solutions
  • Expansion into cardiovascular and neurological disorders
Growth Outlook
  • Recent quarterly revenue of €310.3 million shows strong market demand
  • Trailing twelve months (TTM) revenue growth indicates robust operational performance
  • Strategic partnerships enhance product pipeline and market reach
Financial Highlights
  • TTM net income margin of 5.09% reflects effective cost management
  • Current ratio of 2.31 indicates strong liquidity position
  • Dividend yield of 1.75% offers attractive returns to shareholders
Almirall, S.A. has established itself as a key player in the biopharmaceutical industry, particularly in dermatology. The company's diverse product offerings and strategic partnerships position it well for future growth. Recent financial performance highlights, including a solid revenue stream and healthy liquidity ratios, suggest a stable operational foundation. The focus on innovative treatments and expansion into new therapeutic areas further enhances its growth potential, making it an interesting prospect for investors looking to explore opportunities in the healthcare sector.
AI Generated • Sep 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2,097

CEO

Carlos Gallardo Piqué, MBA

Website

www.almirall.com

Headquarters

Barcelona, 08022, ES

LBTSF Financials

Key Financial Metrics (TTM)

Gross Margin

74.04%

Operating Margin

8.50%

Net Income Margin

5.09%

Return on Equity

4.78%

Return on Capital

3.70%

Return on Assets

3.03%

Earnings Yield

2.08%

Dividend Yield

0.00%

Payout Ratio

5.29%

Stock Overview

Market Cap

$3.34BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

217.78M

Volume

5

Avg. Volume

0

Financials (TTM)

Gross Profit

€1.45B

Operating Income

€580.80M

EBITDA

€480.25M

Operating Cash Flow

€333.85M

Capital Expenditure

-€125.85M

Free Cash Flow

€238.89M

Cash & ST Invst.

€355.41M

Total Debt

€356.11M

Almirall Performance Analysis

Almirall annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 907,251,477-7.2%
20232023-12-31EUR 967,075,2056.6%
20242024-12-31EUR 1,066,245,29410.3%
20252025-12-31EUR 1,250,559,17017.3%
Almirall sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.1%
Q42025-12-31110.4%
Q12026-03-31-46.7%
Q22026-06-306.2%
Almirall annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.02N/A
20232023-12-31EUR -0.21N/A
20242024-12-31EUR 0.05N/A
20252025-12-31EUR 0.24369.0%
Almirall sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30151.9%
Q42025-12-3153.3%
Q12026-03-31-20.6%
Q22026-06-3053.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€310.32M

+13.1%

Gross Profit

€574.44M

+129.9%

Gross Margin

1.85%

N/A

Market Cap

$3.34BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.65M

N/A

Employees

2,026

N/A

Net Income

€24.26M

+387.3%

EBITDA

€74.85M

+54.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€355.41M

+10.0%

Total Debt

€356.11M

-12.0%

Accounts Receivable

€195.86M

+16.0%

Inventory

€173.45M

-3.5%

Long Term Debt

€338.09M

-12.4%

Short Term Debt

€18.02M

-3.4%

Return on Assets

3.03%

N/A

Return on Invested Capital

5.86%

N/A

Free Cash Flow

€5.04M

+112.3%

Operating Cash Flow

€83.93M

+169.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
CURLFCuraleaf Holdings, Inc.
$8.49-3.79%
CASBFCanSino Biologics Inc.
$4.90+0.00%
GTBIFGreen Thumb Industries Inc.
$6.38-0.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$50.66-6.11%
CRWVCoreWeave
$65.56-15.74%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.27+12.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.20-12.83%

Questions About LBTSF

What is the current price of Almirall?

Almirall is trading at $15.35 per share.

What is the 52-week range for Almirall?

Over the past 52 weeks, Almirall has traded between $13.36 and $15.47.

How much debt does Almirall have?

As of the most recent reporting period, Almirall reported total debt of €367.40M.

How much cash does Almirall have on hand?

Almirall reported €405.38M in cash and cash equivalents in its most recent financial results.

What is Almirall’s dividend yield?

Almirall does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services